LAB

Standard BioTools Inc.

$0.67

-4.21%
SectorHealthcareIndustryMedical DevicesCountryUnited States

Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consumables, and assays for clinical and diagnostic uses.

Source: Yahoo Finance
AI summary

Price & performance

1M-16.8%
3M-24.9%
YTD-51.5%
1Y-48.2%
52-week range—
Beta1.53
Full chart and returns against a benchmark

Q-Score

52/ 100

Quality against peers; 50 is the peer median.

Growth38
Risk50
Performance35
Valuation81
Profitability56
Leverage55
Sentiment—
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$85.3M-6.2%
Net income-$74.9M
Net margin-87.8%+64.8 pts
Historical fundamentals

Red flags in filings

1active red flag
Exchange listing noticeJul 24, 2026
Filings, findings and the timeline

Revenue exposure

EMEA42%
Americas36%
Asia Pacific22%
Largest customer12%
Regions, segments, customers and suppliers

Valuation

LABIndustryP/E1.9729.61P/S3.113.49EV/EBITDA—18.38P/B0.473.39PEG——
Dividend yield0.00%
Every valuation metric

Earnings

Nov 3next report
EPS estimate—
Beats (last 4 quarters)—
Average surprise—
EPS revisions (30d)—
Every quarter against its estimate